Compare · AZN vs LNDC
AZN vs LNDC
Side-by-side comparison of AstraZeneca PLC (AZN) and Landec Corporation (LNDC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and LNDC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $244.97B, about 795.1x LNDC ($308.1M).
- AZN has hit the wire 13 times in the past 4 weeks while LNDC has been quiet.
- AZN has more recent analyst coverage (25 ratings vs 5 for LNDC).
- Company
- AstraZeneca PLC
- Landec Corporation
- Price
- $158.00-6.85%
- $8.81-2.76%
- Market cap
- $244.97B
- $308.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 1996
- News (4w)
- 13
- 0
- Recent ratings
- 25
- 5
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Landec Corporation
Landec Corporation, together with its subsidiaries, engages in the design, development, manufacture, and sale of differentiated health and wellness products for food and biomaterials markets. It operates through Curation Foods and Lifecore segments. The Curation Foods segment engages in processing, marketing, and selling of plant-based salads, and fresh-cut and whole processed vegetables primarily under the Eat Smart brand, O branded olive oils and wine vinegars, and Yucatan and Cabo Fresh guacamole and avocado food products, as well as various private labels to retail grocery chains, club stores, and food service operators; and sells BreatheWay packaging products. The Lifecore segment manufactures pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products to treat various medical conditions and procedures. It also provides product development services, including technology transfer, material component changes, analytical method and formulation development, pilot and stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. It operates in the United States, Canada, Belgium, Switzerland, Czech Republic, Ireland, and internationally. The company was incorporated in 1986 and is headquartered in Santa Maria, California.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers
- AstraZeneca results: H1 and Q2 2026
- SEC Form 6-K filed by AstraZeneca PLC
- Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
Latest LNDC
- Landec Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form SCHEDULE 13G filed by Landec Corporation
- SEC Form SC 13G/A filed by Landec Corporation (Amendment)
- Schechter Joshua converted options into 9,554 shares, increasing direct ownership by 20% to 57,667 units (SEC Form 4)
- Calloway Nathaniel converted options into 3,981 shares, increasing direct ownership by 17% to 28,069 units (SEC Form 4)
- Obus Nelson converted options into 9,554 shares, increasing direct ownership by 12% to 88,687 units (SEC Form 4)
- Edwards Jeffrey L converted options into 9,554 shares, increasing direct ownership by 24% to 49,667 units (SEC Form 4)
- Diradoorian Raymond H converted options into 9,554 shares, increasing direct ownership by 31% to 39,978 units (SEC Form 4)
- Houde Lovas Katrina converted options into 9,554 shares, increasing direct ownership by 19% to 59,906 units (SEC Form 4)
- Barbarosh Craig A. converted options into 9,554 shares (SEC Form 4)